Tome Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tome Biosciences, Inc. - overview
Established
2021
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Based in the US and founded in 2021, Tome Biosciences, Inc. is a biotechnology firm that is developing programmable gene insertion technology. The company was co-founded by Omar Abudayyeh and Jonathan Gootenberg. In December 2023, Tome Biosciences Inc.
raised USD 213 million in Series A and B funding investors Andreessen Horowitz, ARCH Venture Partners, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, and Alexandria Venture Investments. The company offers technologies that allow any genetic sequence of any size to be injected into any genome at any location using CRISPR. The firm is working on genomic therapeutics, delivering cures to patients through cell and genome engineering. The startup develops a variant of CRISPR that can insert 36,000 base pairs into the genome at once.
Tome Biosciences, Inc. will use the December 2023 funding to accelerate its genomic integration platform.
Current Investors
ARCH Venture Partners, Andreessen Horowitz, Longwood Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.tome.bio
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.